[1]陈智超,薛奥诺,时金昭.H3K27me3与高级别胶质瘤生存预后的关系[J].中国临床神经外科杂志,2023,28(10):635-638.[doi:10.13798/j.issn.1009-153X.2023.10.008]
　CHEN Zhi-chao,XUE Ao-nuo,SHI Jin-zhao.Relationship between H3K27me3 and survival prognosis of patients with high-grade gliomas[J].,2023,28(10):635-638.[doi:10.13798/j.issn.1009-153X.2023.10.008]
点击复制

H3K27me3与高级别胶质瘤生存预后的关系()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
28
期数:
2023年10期
页码:
635-638
栏目:
论著
出版日期:
2023-10-31

文章信息/Info

Title:
Relationship between H3K27me3 and survival prognosis of patients with high-grade gliomas
文章编号:
1009-153X（2023）10-0635-04
作者:
陈智超; 薛奥诺; 时金昭
210000南京，南京医科大学附属明基医院神经外科（陈智超、薛奥诺、时金昭）
Author(s):
CHEN Zhi-chao;  XUE Ao-nuo;  SHI Jin-zhao
Department of Neurosurgery, Nanjing Medical University Affiliated Mingji Hospital, Nanjing 210000, China
关键词:
高级别胶质瘤; 组蛋白H3第27位赖氨酸三甲基化（H3K27me3）; 基因表达; 生存预后
Keywords:
High grade gliomas;  Trimethylated histone H3 at lysine 27 (H3K27me3);  Prognosis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2023.10.008
文献标志码:
A
摘要:
目的 探讨组蛋白H3第27位赖氨酸三甲基化（H3K27me3）与高级别胶质瘤生存预后的关系。方法 选取2015年6月至2017年9月手术切除的64例高级别胶质瘤标本，另选取颅脑损伤内减压术中切除的非肿瘤脑组织10例为对照，免疫组织化学染色法检测组织H3K27me3表达，根据染色评分分为高表达和低表达。随机选取3例非肿瘤脑组织、3例WHO分级Ⅲ级胶质瘤组织、3例WHO分级Ⅳ级胶质瘤组织，应用免疫印迹法检测H3K27me3的蛋白表达。胶质瘤病人随访截止2022年10月，记录总体生存期。结果 免疫组化染色检测结果显示，高级别胶质瘤组织H3K27me3高表达率（59.37%）明显高于非肿瘤脑组织（20.00%；P<0.05）。免疫印迹法检测结果显示，WHO分级Ⅳ级胶质瘤组织H3K27me3蛋白表达水平明显高于WHO分级Ⅲ级胶质瘤组织和非肿瘤脑组织（P<0.05）。64例胶质瘤中位随访时间为62.23个月，5年生存率为37.5%。多因素Cox回归分析显示，H3K27me3高表达是高级别胶质瘤不良生存预后的独立影响因素（P<0.05）。生存曲线分析显示，H3K27me3高表达高级别胶质瘤病人中位生存期（18个月）明显低于低表达病人（33个月；P<0.05）。结论 H3K27me3在高级别胶质瘤组织中高表达，与病人不良生存预后有关。
Abstract:
Objective To investigate the relationship between expression of trimethylated histone H3 at lysine 27 (H3K27me3) in glioma tissues and survival prognosis of patients with high-grade gliomas. Methods The expressions of H3K27me3 were detected in glioma tissues obtained from 64 patients with high-grade gliomas who underwent surgery from June 2015 to September 2017, and in non-tumor brain tissues obtained from 10 patients with traumatic brain injury who underwent decompression using immunohistochemical staining. The protein expression of H3K27me3 was detected by western blotting in non-tumor brain tissues (n=3), WHO grade Ⅲ glioma tissues (n=3) and WHO grade Ⅳ glioma tissues (n=3). Patients with gliomas were followed up until October 2022 and their overall survival times were recorded. Results Immunohistochemical staining showed that the high expression rate of H3K27me3 in high-grade glioma tissues (59.37%) was significantly higher than that (20.00%) in non-tumor brain tissues (P<0.05). Western blotting showed that H3K27me3 protein expression level in WHO grade Ⅳ glioma tissues was significantly higher than those in WHO grade Ⅲ glioma tissues and non-tumor brain tissues (P<0.05). The median follow-up time of 64 patients with glioma was 62.23 months, and the 5-year survival rate was 37.5%. Multivariate Cox regression analysis showed that high expression of H3K27me3 was an independent risk factor for poor survival prognosis of patients with high-grade gliomas (P<0.05). Survival curve analysis showed that the median survival time (18 months) of patients with high H3K27me3 expression was significantly lower than that of patients with low H3K27ME3 expression (33 months; P<0.05). Conclusions H3K27me3 is highly expressed in high-grade gliomas, which is associated with poor survival prognosis of patients.

参考文献/References:

[1]AGGARWAL P, LUO W, PEHLIVAN KC, et al. Pediatricversus adult high grade glioma: immunotherapeutic andgenomic considerations [J]. Front Immunol, 2022, 13(5):1038096.
[2]RODRíGUEZ-CAMACHO A, FLORES-VáZQUEZ JG, MOSCARDINIMARTELLI J, et al. Glioblastoma treatment: state-of-the-art and future perspectives [J]. Int J Mol Sci, 2022, 23(13): 7207.
[3]RAAS MWD, ZIJLMANS DW, VERMEULEN M, et al. There is another: H3K27me3-mediated genomic imprinting [J]. Trends Genet, 2022, 38(1): 82-96.
[4]MARSOLIER J, PROMPSY P, DURAND A, et al. H3K27me3 conditions chemotolerance in triple-negative breast cancer [J]. Nat Genet, 2022, 54(4): 459-468.
[5]CHEN X, DENG Y, HUANG C, et al. RUNX3/H3K27me3 Coexpression defines a better prognosis in surgically resected stage Ⅰ and postoperative chemotherapy-naive non-small-cell lung cancer [J]. J Oncol, 2022, 2022(3): 5752263.
[6]司昊天，任虹宇，王晓斌，等. 脑膜瘤组织中H3 K27 me3的表达及临床意义[J]. 实用癌症杂志，2022，37（12）：1939-1941.
[7]张朋肖，吴红记，甘　宁，等. 人脑胶质瘤FAM46A表达与病人预后的关系[J]. 中国临床神经外科杂志，2022，27（3）：171-173.
[8]朱　焱，王伊旻，徐晓婷. 成人高级别胶质瘤患者的预后影响因素分析[J]. 医学研究杂志，2022，51（10）：156-160.
[9]RALLIS KS, GEORGE AM, WOZNIAK AM, et al. Molecular genetics and targeted therapies for paediatric highgrade glioma [J]. Cancer Genomics Proteomics, 2022, 19(4): 390-414.
[10]UDDIN MS, MAMUN AA, ALGHAMDI BS, et al. Epigenetics of glioblastoma multiforme: from molecular mechanismsto therapeutic approaches [J]. Se min Cancer Biol, 2022, 83(8): 100-120.
[11]GUSYATINER O, HEGI ME. Glioma epigenetics: from subclassification to novel treatment options [J]. Se min Cancer Biol, 2018, 51(8): 50-58.
[12]LI Y, GOLDBERG EM, CHEN X, et al. Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas [J]. Mol Cell, 2022, 82(20): 3901-3918.e3907.
[13]ZHANG H, LIU Y, XIE Y, et al. H3K27me3 shapes DNA methylome by inhibiting UHRF1-mediated H3 ubiquitination [J]. Sci China Life Sci, 2022, 65(9): 1685-1700.
[14]DAY CA, HINCHCLIFFE EH, ROBINSON JP. H3K27me3 in diffuse midline glioma and epithelial ovarian cancer: opposing epigenetic changes leading to the same poor outcomes [J]. Cells, 2022, 11(21): 3376.
[15]宫　睿，刘　暌，陈劲草，等. H3K27M及其甲基化在弥漫性脊髓胶质瘤中的表达及与预后的关系[J]. 中国癌症防治杂志，2022，14（2）：167-170.

相似文献/References:

[1]陈正和　陈忠平.高级别胶质瘤的治疗现状及思考[J].中国临床神经外科杂志,2016,(06):350.[doi:10.13798/j.issn.1009-153X.2016.06.010]
[2]毛承亮,唐凯,郑聪颖,等.荧光素钠引导下高级别胶质瘤的手术治疗[J].中国临床神经外科杂志,2017,(02):68.[doi:10.13798/j.issn.1009-153X.2017.02.002]
　MAO Cheng-liang,TANG Kai,ZHENG Cong-ying,et al.Sodium fluorescein-guided surgery for high-grade gliomas[J].,2017,(10):68.[doi:10.13798/j.issn.1009-153X.2017.02.002]
[3]王翅鹏　黄文才 熊 飞　王 叶　姚 顺　曹成龙　马廉亭　徐国政.ADC直方图在高级别胶质瘤与脑单发转移瘤鉴别中的应用价值[J].中国临床神经外科杂志,2018,(07):449.[doi:10.13798/j.issn.1009-153X.2018.07.001]
　WANG Chi-peng,HUANG Wen-cai,XIONG Fei,et al.Value of apparent diffusion coefficient histogram to differentiating high-grade glioma from solitary brain metastasis[J].,2018,(10):449.[doi:10.13798/j.issn.1009-153X.2018.07.001]
[4]王亦强　张国安　贾宏波　朱思远.扩散峰度成像鉴别诊断高级别胶质瘤与脑转移瘤的临床价值[J].中国临床神经外科杂志,2019,(12):730.[doi:10.13798/j.issn.1009-153X.2019.12.004]
　WANG Yi-qiang,ZHANG Guo-an,JIA Hong-bo,et al.Value of diffusion peak imaging to differential diagnosis of WHO high-grade gliomas and solitary brain metastases[J].,2019,(10):730.[doi:10.13798/j.issn.1009-153X.2019.12.004]
[5]陈科宇　江普查.瘤周水肿与人脑高级别胶质瘤预后的相关性[J].中国临床神经外科杂志,2021,26(05):352.[doi:10.13798/j.issn.1009-153X.2021.05.011]
　CHEN Ke-yu,JIANG Pu-cha..Correlation between peritumoral edema of high-grade glioma and patients’ prognoses[J].,2021,26(10):352.[doi:10.13798/j.issn.1009-153X.2021.05.011]
[6]刘宝辉　孙　前　袁凡恩等.高级别胶质瘤的治疗进展[J].中国临床神经外科杂志,2021,26(05):380.[doi:10.13798/j.issn.1009-153X.2021.05.022]
[7]黄露露,张孟贤,于世英.细胞间网络连接在高级别胶质瘤中的作用研究进展[J].中国临床神经外科杂志,2022,27(01):51.[doi:10.13798/j.issn.1009-153X.2022.01.019]
[8]窦志金,袁波,段勇刚.岛叶高级别胶质瘤的手术疗效分析[J].中国临床神经外科杂志,2022,27(07):558.[doi:10.13798/j.issn.1009-153X.2022.07.009]
　DOU Zhi-jin,YUAN Bo,DUAN Yong-gang.Clinical efficacy of surgical resection for high-grade gliomas in the insular lobe[J].,2022,27(10):558.[doi:10.13798/j.issn.1009-153X.2022.07.009]

备注/Memo

备注/Memo:
（2023-08-09收稿，2023-09-11修回）
基金项目：南京市医学科技发展资金（QRX21099）
更新日期/Last Update: 2023-10-31